Susan Halabi

Active 1992–2025

154
Papers
28,114
Citations
81
h-index
147
i10-index

Citations

Citations per year for Susan Halabi1943: 1 citations1993: 1 citations1994: 3 citations1995: 8 citations1996: 12 citations1997: 8 citations1998: 6 citations1999: 17 citations2000: 21 citations2001: 43 citations2002: 54 citations2003: 67 citations2004: 97 citations2005: 122 citations2006: 104 citations2007: 113 citations2008: 139 citations2009: 189 citations2010: 222 citations2011: 237 citations2012: 186 citations2013: 208 citations2014: 181 citations2015: 159 citations2016: 195 citations2017: 189 citations2018: 202 citations2019: 707 citations2020: 862 citations2021: 924 citations2022: 697 citations2023: 562 citations2024: 925 citations2025: 473 citations2026: 25 citations1944–1992: no citations, so these years are not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 3,272 citing papers, 27% of this breakdownUnited Kingdom: 919 citing papers, 7.6% of this breakdownItaly: 712 citing papers, 5.9% of this breakdownCanada: 664 citing papers, 5.5% of this breakdownChina: 661 citing papers, 5.4% of this breakdownGermany: 632 citing papers, 5.2% of this breakdownFrance: 577 citing papers, 4.8% of this breakdownSpain: 415 citing papers, 3.4% of this breakdownAustralia: 404 citing papers, 3.3% of this breakdownJapan: 366 citing papers, 3% of this breakdownNetherlands: 341 citing papers, 2.8% of this breakdownBelgium: 314 citing papers, 2.6% of this breakdown
0%27%Other 23.5%

Fields

  • Medicine80.2%
  • Biochemistry, Genetics and Molecular Biology13.1%
  • Immunology and Microbiology2.3%
  • Computer Science0.8%
  • Mathematics0.5%
  • Nursing0.5%
  • Other2.6%

Topics

  • Prostate Cancer Treatment and Research14%
  • Prostate Cancer Diagnosis and Treatment8.5%
  • Radiopharmaceutical Chemistry and Applications4.1%
  • Cancer Genomics and Diagnostics3.1%
  • Renal cell carcinoma treatment3.1%
  • Cancer Immunotherapy and Biomarkers3%
  • Other64.2%

Coauthors

All papers

Open in search
  1. Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Peter S. Nelson, Lawrence H. Schwartz, Susan Halabi, Philip W. Kantoff, Andrew J. Armstrong - Journal of Clinical Oncology 2016 cited by 1,603

  2. The Lancet Commission on prostate cancer: planning for the surge in cases

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Anwar R. Padhani, Charles Parker, Hannah Rush, Mark Sculpher, Howard R. Soule, Matthew R. Sydes, Derya Tilki, Nina Tunariu, Paul Villanti, Liping Xie - The Lancet 2024 cited by 643

  3. Management of patients with advanced prostate cancer—metastatic and/or castration-resistant prostate cancer: Report of the Advanced Prostate Cancer Consensus Conference (APCCC) 2022

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Noel W. Clarke, Gedske Daugaard, Maria De Santis, Ignacio Durán, Ross Eeles, Eleni Efstathiou, Jason A. Efstathiou, Onyeanunam Ngozi Ekeke, Christopher P. Evans, Stefano Fanti, Felix Y. Feng, Valérie Fonteyne, Nicola Fossati, Mark Frydenberg, Dan George, Martin Gleave, Gwénaëlle Gravis, Susan Halabi, Daniel Heinrich, Ken Herrmann, Celestia Higano, Michael S. Hofman, Lisa G. Horvath, Maha Hussain, Barbara Alicja Jereczek‐Fossa, Robert J. Jones, Ravindran Kanesvaran, Pirkko‐Liisa Kellokumpu‐Lehtinen, Raja B. Khauli, Laurence Klotz, Gero Kramer, Raja Leibowitz, Christopher Logothetis, Brandon A. Mahal, Fernando Cotait Maluf, Joaquı́n Mateo, David Matheson, Niven Mehra, Axel S. Merseburger, Amee Morgans, Michael J. Morris, Hind M’rabti, Deborah Mukherji, Declan G. Murphy, Vedang Murthy, Paul L. Nguyen, William Oh, Piet Ost, Joe M. O’Sullivan, Anwar R. Padhani, Carmel Pezaro, Darren M.C. Poon, Colin C. Pritchard, Danny Rabah, Dana E. Rathkopf, Robert E. Reiter, Mark A. Rubin, Charles J. Ryan, Fred Saad, Juan Pablo Sade, Oliver Sartor, Howard I. Scher, Nima Sharifi, Iwona Skoneczna, Howard R. Soule, Daniel E. Spratt, Sandy Srinivas, Cora N. Sternberg, Thomas Steuber, Hiroyoshi Suzuki and 18 more - European Journal of Cancer 2023 cited by 157

  4. Design and End Points of Clinical Trials for Patients With Progressive Prostate Cancer and Castrate Levels of Testosterone: Recommendations of the Prostate Cancer Clinical Trials Working Group

    Authors: , , , , , , , , , , , , , , , , , , , - Journal of Clinical Oncology 2008 cited by 2,241

  5. Prospective Multicenter Validation of Androgen Receptor Splice Variant 7 and Hormone Therapy Resistance in High-Risk Castration-Resistant Prostate Cancer: The PROPHECY Study

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , - Journal of Clinical Oncology 2019 cited by 364

  6. Meta-Analysis Evaluating the Impact of Site of Metastasis on Overall Survival in Men With Castration-Resistant Prostate Cancer

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , - Journal of Clinical Oncology 2016 cited by 463

  7. Metastasis-Free Survival Is a Strong Surrogate of Overall Survival in Localized Prostate Cancer

    Authors: , , , , , , , , , , , , , , , , , - Journal of Clinical Oncology 2017 cited by 434

  8. Association of Black Race With Prostate Cancer–Specific and Other-Cause Mortality

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , - JAMA Oncology 2019 cited by 409

  9. Management of Patients with Advanced Prostate Cancer. Part I: Intermediate-/High-risk and Locally Advanced Disease, Biochemical Relapse, and Side Effects of Hormonal Treatment: Report of the Advanced Prostate Cancer Consensus Conference 2022

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Noel W. Clarke, Gedske Daugaard, Maria De Santis, Ignacio Durán, Rosalind A. Eeles, Eleni Efstathiou, Jason A. Efstathiou, Onyeanunam Ngozi Ekeke, Christopher P. Evans, Stefano Fanti, Felix Y. Feng, Valérie Fonteyne, Nicola Fossati, Mark Frydenberg, Daniel J. George, Martin Gleave, Gwénaëlle Gravis, Susan Halabi, Daniel Heinrich, Ken Herrmann, Celestia S. Higano, Michael S. Hofman, Lisa G. Horvath, Maha Hussain, Barbara Alicja Jereczek‐Fossa, Robert J. Jones, Ravindran Kanesvaran, Pirkko‐Liisa Kellokumpu‐Lehtinen, Raja B. Khauli, Laurence Klotz, Gero Kramer, Raya Leibowitz‐Amit, Christopher J. Logothetis, Brandon A. Mahal, Fernando Cotait Maluf, Joaquı́n Mateo, David Matheson, Niven Mehra, Axel S. Merseburger, Alicia K. Morgans, Michael J. Morris, Hind M’rabti, Deborah Mukherji, Declan G. Murphy, Vedang Murthy, Paul L. Nguyen, William Oh, Piet Ost, Joe M. O’Sullivan, Anwar R. Padhani, Carmel Pezaro, Darren M.C. Poon, Colin C. Pritchard, Danny Rabah, Dana E. Rathkopf, Robert E. Reiter, Mark A. Rubin, Charles J. Ryan, Fred Saad, Juan Pablo Sade, Oliver A. Sartor, Howard I. Scher, Nima Sharifi, Iwona Skoneczna, Howard R. Soule, Daniel E. Spratt, Sandy Srinivas, Cora N. Sternberg, Thomas Steuber, Hiroyoshi Suzuki and 18 more - European Urology 2022 cited by 118

  10. Cabozantinib Versus Sunitinib As Initial Targeted Therapy for Patients With Metastatic Renal Cell Carcinoma of Poor or Intermediate Risk: The Alliance A031203 CABOSUN Trial

    Authors: , , , , , , , , , , , , - Journal of Clinical Oncology 2017 cited by 715

  11. Everolimus versus sunitinib for patients with metastatic non-clear cell renal cell carcinoma (ASPEN): a multicentre, open-label, randomised phase 2 trial

    Authors: , , , , , , , , , , , , , , , , , , , - The Lancet Oncology 2016 cited by 424

  12. Adjuvant Pembrolizumab versus Observation in Muscle-Invasive Urothelial Carcinoma

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Cecilia Mitchell, Alan W.C. Tan, Howard Streicher, Elad Sharon, Helen Moon, Michael Woods, Susan Halabi, Gabriela Perez Burbano, Michael J. Morris, Jonathan E. Rosenberg - New England Journal of Medicine 2024 cited by 145

  13. Pertuzumab Plus Trastuzumab in Patients With Colorectal Cancer WithERBB2Amplification orERBB2/3Mutations: Results From the TAPUR Study

    Authors: , , , , , , , , , , - JCO Precision Oncology 2022 cited by 61

  14. Cabozantinib versus sunitinib as initial therapy for metastatic renal cell carcinoma of intermediate or poor risk (Alliance A031203 CABOSUN randomised trial): Progression-free survival by independent review and overall survival update

    Authors: , , , , , , , , , , , , , , , - European Journal of Cancer 2018 cited by 400

  15. Pembrolizumab in Patients With Metastatic Breast Cancer With High Tumor Mutational Burden: Results From the Targeted Agent and Profiling Utilization Registry (TAPUR) Study

    Authors: , , , , , , , , , , , , , , , , , , , - Journal of Clinical Oncology 2021 cited by 182

  16. Cardiovascular Safety of Degarelix Versus Leuprolide in Patients With Prostate Cancer: The Primary Results of the PRONOUNCE Randomized Trial

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Thomas J. Povsic, Michael Morse, Kenneth W. Mahaffey, Susan Halabi, Darryl P. Leong, Laurence Klotz, Neil Fleshner, G. Kenneth Jansz, Jonathan Giddens, R. Blair Egerdie, Joseph L. Chin, Joseph Zadra, Richard Casey, Jean Simard, Tamim Niazi, André‐Guy Martin, Marek Babjuk, Jaroslav Hájek, Jiří Klečka, Jiří Kubeš, Jan Schraml, Jitka Jakesova, J Vaňásek, Bohuslav Melichar, Heikki Seikkula, M. Abdiche, Marc Colombel, P. Debourdeau, G. Robert, Arnauld Villers, Guillaume Ploussard, Benjamin Pradère, F. Bruyère, Jean‐Luc Descotes, Idir Ouzaïd, Alexander Winter, Herbert Hanitzsch, H. Sperling, Ralf Eckert, Peter Hammerer, E. Stagge, F. Seseke, Silvio Szymula, Aristotelis Bamias, A. Thanos, Konstantinos Hatzimouratidis, Charalambos Mamoulakis, Haralabos P. Kalofonos, Elżbieta Oszukowska, Katarzyna Madziarska, Jacek Fijuth, Mateusz Obarzanowski, B. Yа. Alekseev, Vagif Atduev, Dmitri Pushkar, Evgeniy Veliev, A. V. Zyryаnov, С Б Петров, Evgeny Kopyltsov, Vadim Kozlov, Ladislav Macko, J. Dúbravický, Richard Polak, Obaidullah Mir, Marek Vargovcak, I. Minčík, J. Kliment, Frederico Gonçalves, J Mikuláš, Roman Sokol and 55 more - Circulation 2021 cited by 143

  17. Management of Patients with Advanced Prostate Cancer: The Report of the Advanced Prostate Cancer Consensus Conference APCCC 2017

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Gero Kramer, Chris Logothetis, Fernando Cotait Maluf, Alicia K. Morgans, Michael J. Morris, Nicolas Mottet, Vedang Murthy, William Oh, Piet Ost, Anwar R. Padhani, Chris Parker, Colin C. Pritchard, Mack Roach, Mark A. Rubin, Charles J. Ryan, Fred Saad, Oliver Sartor, Howard I. Scher, Avishay Sella, Neal D. Shore, Matthew R. Smith, Howard R. Soule, Cora N. Sternberg, Hiroyoshi Suzuki, Christopher J. Sweeney, Matthew R. Sydes, Ian F. Tannock, Bertrand Tombal, R. Valdagni, Thomas Wiegel, Aurelius Omlin - European Urology 2017 cited by 643

  18. Abatacept, Cenicriviroc, or Infliximab for Treatment of Adults Hospitalized With COVID-19 Pneumonia

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Luis Parra-Rodriguez, Tatyana Der, Kate Willsey, Jun Wen, A Silverstein, Sean M. O’Brien, Hussein R. Al‐Khalidi, Michael A. Maldonado, Richard Melsheimer, William Ferguson, Steven E. McNulty, Pearl Zakroysky, Susan Halabi, Daniel K. Benjamin, Sandra Butler, Jane C. Atkinson, Stacey J. Adam, Soju Chang, Lisa M. LaVange, Michael A. Proschan, Samuel A. Bozzette, William G. Powderly, ACTIV-1 IM Study Group Members, Mihir Patel, Arun J. Sanyal, Jason Green, Huimin Wu, Benjamin P. Linas, Philip Grant, Vivek Iyer, Otto O. Yang, Bindu Balani, Sam Parnia, Ryan K Dare, Caryn G. Morse, Estelle S. Harris, Glenn Wortmann, Nicholas S. Hill, Shama Patel, Julia Garcia‐Diaz, Suman Thapamager, Megan Devine, Christine M. Bojanowski, Barry Meisenberg, Gailen D. Marshall, Dima Dandachi, Arick P. Sabin, Anthony Breemo, Suman Sinha, Christopher H. Goss, Rebecca Reece, Arlette Aouad, Seth Glassman, Peter E. Morris, Bela Patel, Fatimah Bello, Juliana Cardozo Fernandes, Oscar Carbajal, L Ravera, Mozar Castro, Miguel Villegas-Chiroque, Fernando Riera, A. Casado Camacho, Claudio Stadnik, Jorge Gave, Rodrigo Biondi, Ronal Gamarra Velarde, José Cerbino Neto, J. Ditondo, Marcelo Losso and 258 more - JAMA 2023 cited by 67

  19. Updated Prognostic Model for Predicting Overall Survival in First-Line Chemotherapy for Patients With Metastatic Castration-Resistant Prostate Cancer

    Authors: , , , , , , , - Journal of Clinical Oncology 2014 cited by 475

  20. Management of Patients with Advanced Prostate Cancer: Report of the Advanced Prostate Cancer Consensus Conference 2019

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Philip W. Kantoff, Raja B. Khauli, Raya Leibowitz‐Amit, Chris Logothetis, Fernando Cotait Maluf, Robin Millman, Alicia K. Morgans, Michael J. Morris, Nicolas Mottet, Hind M’rabti, Declan G. Murphy, Vedang Murthy, William Oh, Piet Ost, Joe M. O’Sullivan, Anwar R. Padhani, Chris Parker, Darren M.C. Poon, Colin C. Pritchard, Robert E. Reiter, Mack Roach, Mark A. Rubin, Charles J. Ryan, Fred Saad, Juan Pablo Sade, Oliver Sartor, Howard I. Scher, Neal D. Shore, Eric J. Small, Matthew R. Smith, Howard R. Soule, Cora N. Sternberg, Thomas Steuber, Hiroyoshi Suzuki, Christopher J. Sweeney, Matthew R. Sydes, Mary-Ellen Taplin, Bertrand Tombal, Levent Türkeri, Inge M. van Oort, A. Zapatero, Aurelius Omlin - European Urology 2020 cited by 395

  21. Rationale and Design of the Targeted Agent and Profiling Utilization Registry Study

    Authors: , , , , , , , , , , , , - JCO Precision Oncology 2018 cited by 180

  22. Pembrolizumab in Patients With Tumors With High Tumor Mutational Burden: Results From the Targeted Agent and Profiling Utilization Registry Study

    Authors: , , , , , , , , , , , , , , , , , , , , , , , - Journal of Clinical Oncology 2023 cited by 41

  23. Prostate Cancer Racial Disparities: A Systematic Review by the Prostate Cancer Foundation Panel.

    Authors: , , , , , , , , , , - European Urology Oncology 2021 cited by 96

  24. Randomized Phase III Study of Enzalutamide Compared With Enzalutamide Plus Abiraterone for Metastatic Castration-Resistant Prostate Cancer (Alliance A031201 Trial)

    Authors: , , , , , , , , , , , , , , , , , , , , , , - Journal of Clinical Oncology 2023 cited by 52